BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 36247843)

  • 21. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
    Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
    Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 3T diffusion-weighted MRI and
    Lee SY; Jee WH; Yoo IR; Jung JY; Im SA; Chung YG; Kang JH
    Br J Radiol; 2019 Oct; 92(1102):20181051. PubMed ID: 31322913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
    Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
    Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone metastases with "false negative" findings on 18F-FDG PET/CT in patients with angiosarcoma: A case series with literature review.
    Ariga A; Matsumoto S; Tanizawa T; Hayakawa K; Minami Y; Saito M; Kurosawa N; Yamashita K; Terauchi T; Ae K
    Medicine (Baltimore); 2023 Jul; 102(28):e34196. PubMed ID: 37443509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients.
    Bruckmann NM; Kirchner J; Umutlu L; Fendler WP; Seifert R; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Antke C; Schimmöller L; Ingenwerth M; Breuckmann K; Stang A; Buchbender C; Antoch G; Sawicki LM
    Eur Radiol; 2021 Nov; 31(11):8714-8724. PubMed ID: 33912991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
    Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS
    Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-body [¹⁸F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results.
    Beiderwellen K; Huebner M; Heusch P; Grueneisen J; Ruhlmann V; Nensa F; Kuehl H; Umutlu L; Rosenbaum-Krumme S; Lauenstein TC
    Eur Radiol; 2014 Aug; 24(8):2023-30. PubMed ID: 24907940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
    Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
    Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-Body [
    Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
    Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.
    Daldrup-Link HE; Franzius C; Link TM; Laukamp D; Sciuk J; Jürgens H; Schober O; Rummeny EJ
    AJR Am J Roentgenol; 2001 Jul; 177(1):229-36. PubMed ID: 11418435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
    Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
    Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer.
    Al-Muqbel KM; Yaghan RJ
    Medicine (Baltimore); 2016 May; 95(21):e3753. PubMed ID: 27227942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.